<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691571</url>
  </required_header>
  <id_info>
    <org_study_id>831401</org_study_id>
    <nct_id>NCT03691571</nct_id>
  </id_info>
  <brief_title>Esophageal Cooling for AF Ablation</brief_title>
  <acronym>eCoolAF</acronym>
  <official_title>Utility of Esophageal Cooling Therapy for the Prevention of Thermal Injury During Atrial Fibrillation Ablation (eCoolAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Attune Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if esophageal cooling using the Attune Medical
      Esophageal Heat Transfer Device (EnsoETM) limits the number or seriousness of injury to the
      esophagus during atrial fibrillation ablation procedures. The EnsoETM is an FDA cleared
      device used for temperature management, but is not routinely used during atrial fibrillation
      ablation procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the
      purpose of cooling or warming a patient while simultaneously allowing gastric decompression
      and drainage. Modulation and control of the patient's temperature is achieved by connecting
      the EnsoETM to an external heat exchanger. Two lumens connect to the external heat exchanger,
      while a third central lumen provides stomach access for connection to a fluid collection
      device with low intermittent suction for gastric decompression. The EnsoETM is made of
      standard medical-grade silicone. It is a single-use, disposable, non-implantable device with
      an intended duration of use of 72 hours or less. Distilled water circulates within the
      EnsoETM just like a water blanket.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, blinded single center pilot study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal thermal injury between groups measured by EGD</measure>
    <time_frame>Day 1 to 2</time_frame>
    <description>Any injury, occurrence rate measured by EGD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Esophageal injury between groups</measure>
    <time_frame>Day 1 to 2</time_frame>
    <description>The severity and size of injury measured by EGD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posterior wall ablation parameters: Temperature</measure>
    <time_frame>Day 0</time_frame>
    <description>initial and maximum temperatures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posterior wall ablation parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>Impedance drop (absolute difference)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute PV reconnection</measure>
    <time_frame>Day 0</time_frame>
    <description>PV reconnection present or no as recorded in Carto</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of acute PV reconnection</measure>
    <time_frame>Day 0</time_frame>
    <description>Location of PV reconnection present or no as recorded in Carto</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF</measure>
    <time_frame>3 months, 6 months, and 12 months</time_frame>
    <description>Clinically documented Atrial Fibrillation via review of multiple data sources in clinical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Esophageal Cooling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophageal Cooling</intervention_name>
    <description>The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.</description>
    <arm_group_label>Esophageal Cooling</arm_group_label>
    <other_name>Attune Medical Esophageal Heat Transfer Device</other_name>
    <other_name>EnsoETM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard of care involves standard temperature probe monitoring.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients above the age of 18 years old.

          2. Patients with the diagnosis of atrial fibrillation undergoing clinically indicated
             de-novo AF ablation procedure.

          3. Patients must be able to understand and critically review the informed consent form.

        Exclusion Criteria:

          1. Patients whom are unable to provide informed consent.

          2. Patients with contraindication to EGD.

          3. History of prior AF ablation procedures.

          4. Significant co-morbidities that preclude standard ablation procedure.

          5. Patient is ineligible for EnsoETM placement due to:

               -  Known esophageal deformity or evidence of esophageal trauma (for example history
                  of esophagectomy, previous swallowing disorders, achalasia).

               -  Known ingestion of acidic or caustic poisons within the prior 24 hours.

               -  Patients with &lt;40 kg of body mass.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pasquale Santangeli, MD,PhD</last_name>
    <phone>215-662-6005</phone>
    <email>pasquale.santangeli@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cory Tschabrunn, PhD, CEPS</last_name>
    <phone>215-614-0482</phone>
    <email>cory.tschabrunn@uphs.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Sharkoski, MPH, MBE</last_name>
      <phone>215-615-2354</phone>
      <email>tiffany.sharkoski@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Pasquale Santangeli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cory M Tschabrunn, PhD, CEPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

